Curis (NASDAQ:CRIS) Stock Price Passes Above Two Hundred Day Moving Average of $0.71

Shares of Curis, Inc. (NASDAQ:CRIS – Get Rating) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.71 and traded as high as $0.88. Curis shares last traded at $0.81, with a volume of 151,384 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, StockNews.com started coverage on Curis in a report on Thursday, May 18th. They issued a “hold” rating on the stock.

Curis Stock Performance

The stock has a market capitalization of $78.26 million, a PE ratio of -1.47 and a beta of 2.93. The business has a 50 day moving average of $0.75 and a two-hundred day moving average of $0.71.

Curis (NASDAQ:CRIS – Get Rating) last posted its earnings results on Thursday, May 4th. The biotechnology company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.01). The company had revenue of $2.30 million for the quarter, compared to analyst estimates of $2.49 million. Curis had a negative return on equity of 103.76% and a negative net margin of 501.08%. During the same period last year, the business earned ($0.18) earnings per share. On average, equities analysts expect that Curis, Inc. will post -0.47 EPS for the current fiscal year.

Institutional Investors Weigh In On Curis

A number of institutional investors have recently modified their holdings of CRIS. HRT Financial LP acquired a new stake in shares of Curis in the fourth quarter valued at $29,000. Engineers Gate Manager LP purchased a new position in Curis in the first quarter valued at $32,000. UBS Group AG boosted its holdings in Curis by 183.6% in the third quarter. UBS Group AG now owns 51,332 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 33,231 shares during the period. Virtu Financial LLC purchased a new position in Curis in the fourth quarter valued at $51,000. Finally, Bank of Montreal Can purchased a new position in Curis in the second quarter valued at $59,000. 38.72% of the stock is owned by institutional investors and hedge funds.

Curis Company Profile

(Get Rating)

Curis, Inc engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints.